The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Open accessAbstract
BACKGROUND: Patients with diffuse large B-cell lymphoma that is refractory to primary and second-line therapies or that has relapsed after stem-cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel targets and eliminates CD19-expressing B cells and showed efficacy against B-cell lymphomas in a single-center, phase 2a study. METHODS: We conducted an international, phase 2, pivotal study of centrally manufactured tisagenlecleucel involving adult patients with relapsed or refractory diffuse large B-cell lymphoma who were ineligible for or had disease progression after autologous hematopoietic stem-cell transplantation. The primary end point was the best overall response rate (i.e., the percentage of patients who had a complete or partial response), as judged by an independent review committee. RESULTS: A total of 93 patients received an infusion and were included in the evaluation of efficacy. The median time from infusion to data cutoff was 14 months (range, 0.1 to 26). The best overall response rate was 52% (95% confidence interval, 41 to 62); 40% of the patients had complete responses, and 12% had partial responses. Response rates were consistent across prognostic subgroups. At 12 months after the initial response, the rate of relapse-free survival was estimated to be 65% (79% among patients with a complete response). The most common grade 3 or 4 adverse events of special interest included cytokine release syndrome (22%), neurologic events (12%), cytopenias lasting more than 28 days (32%), infections (20%), and febrile neutropenia (14%). Three patients died from disease progression within 30 days after infusion. No deaths were attributed to tisagenlecleucel, cytokine release syndrome, or cerebral edema. No differences between response groups in tumor expression of CD19 or immune checkpoint-related proteins were found. CONCLUSIONS: In this international study of CAR T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma in adults, high rates of durable responses were produced with the use of tisagenlecleucel. (Funded by Novartis; JULIET ClinicalTrials.gov number, NCT02445248 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These CAR T-cells were able to elicit complete responses (CR) in 32-67% of lymphoma patients and showed better CR rates in patients with leukemia (16-19).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [17]
In the citing paper
“However, despite high initial response rates, complete and long-term remission is only achieved in up to 40% of patients13–16.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [16]
In the citing paper
“Efficacy results seem similar in patients with LBCL treated with CD19 CAR T cells costimulated by 4-1BB instead of CD28, with or without fixing the ratio of CD4:CD8 cells.”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Self-citationTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Self-citationChimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Schuster, S. J., Svoboda, J., Chong, E. A., Nasta, S. D., Mato, A. R., Anak, Ö., Brogdon, J. L., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,891
Self-citationOutcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Neste, É. V. D., Kuruvilla, J. G., Westin, J. R., Link, B. K., Hay, A. E., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,755
Self-citationPorter, D. L., Hwang, W.-T., Frey, N. V., Lacey, S. F., Shaw, P. A., Loren, A. W., Bagg, A., Marcucci, K. T., Shen, A., Gonzalez, V., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5415 · Cited by 1,729
Gisselbrecht, C., Glaß, B., Mounier, N., Gill, D. S., Linch, D. C., Trněný, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,639
Flagged first, then by citations
1 of the 29 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Schuster SJ, Bishop MR, Tam CS, et al. Primary analysis of JULIET: a global, pivotal, phase 2 trial of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma. Blood 2017;130:577-577. abstract.
- Maude SL, Grupp SA, Pulsipher MA, et al. Analysis of safety data from 2 multicenter trials of CTL019 in pediatric and young adult patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL). Haematologica 2017;102:197-198.
Cited by
Sorted by citations
Items 601–700 of 1,010
Magnetic Particle Imaging: From Tracer Design to Biomedical Applications in Vasculature Abnormality
Xie, X., Zhai, J., Zhou, X., Guo, Z., Lo, P., Zhu, G., Chan, K. W. Y., & Yang, M. (2023) · Advanced Materials · doi:10.1002/adma.202306450 · Cited by 57
Overview of approved CAR-T products and utility in clinical practice
Bhaskar, S., Dholaria, B., Savani, B. N., Sengsayadeth, S. M., & Oluwole, O. O. (2024) · Clinical Hematology International · doi:10.46989/001c.124277 · Cited by 67
Huemer, F., Leisch, M., Geisberger, R., Melchardt, T., Rinnerthaler, G., Zaborsky, N., & Greil, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082856 · Cited by 60
Complications after CD19+ CAR T-Cell Therapy
Penack, O., & Koenecke, C. (2020) · Cancers · doi:10.3390/cancers12113445 · Cited by 59
Ernst, M., Oeser, A., Besiroglu, B., Caro-Valenzuela, J., Aziz, M. A. A. E., Monsef, I., Borchmann, P., Estcourt, L. J., Skoetz, N., & Goldkuhle, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013365.pub2 · Cited by 57
Self-citationGutiérrez, C., Brown, A. R., Herr, M. M., Kadri, S. S., Hill, B. T., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K. B., Lin, Y., et al. (2020) · Journal of Critical Care · doi:10.1016/j.jcrc.2020.04.008 · Cited by 55
Ghafouri, S. N., Timmerman, J. M., Larson, S. M., & Mead, M. D. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01099-4 · Cited by 56
Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer
Dorff, T. B., Narayan, V., Forman, S. J., Zang, P. D., Fraietta, J. A., June, C. H., Haas, N. B., & Priceman, S. J. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1483 · Cited by 59
Rejeski, K., dos Santos, D. M. C., Parker, N. H., Bücklein, V., Winkelmann, M., Jhaveri, K. S., Liu, L., Trinkner, P., Günther, S., Karschnia, P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0487 · Cited by 56
Clinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets
Miao, Y., Medeiros, L. J., Xu-Monette, Z. Y., Li, J., & Young, K. H. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00107 · Cited by 56
Zhou, X., Tu, S., Wang, C., Huang, R., Deng, L., Song, C., Yue, C., He, Y., Yang, J., Zhao, L., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.564099 · Cited by 57
Elnair, R. A., Ellithi, M., Kallam, A., Shostrom, V., & Bociek, R. G. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04603-y · Cited by 55
Hong, R., Yin, E. T. S., Wang, L., Zhao, X., Zhou, L., Wang, G., Zhang, M., Zhao, H., Wei, G., Wang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713577 · Cited by 55
Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges
Xiao, B., Zhang, J., Zhu, Y., Cui, X., Lu, Z., Yu, B., & Wu, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.782775 · Cited by 57
The critical role of tumor microbiome in cancer immunotherapy
Yang, L., Wang, Q., He, L., & Sun, X. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2301801 · Cited by 54
Luo, W., Li, C., Zhang, Y., Du, M., Kou, H., Lu, C., Mei, H., & Hu, Y. (2022) · BMC Cancer · doi:10.1186/s12885-021-09102-x · Cited by 57
Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL
Gauthier, J., Gazeau, N., Hirayama, A. V. V., Hill, J. A., Wu, V., Cearley, A., Perkins, P., Kirk, A., Shadman, M. S., Chow, V. A., et al. (2022) · Blood · doi:10.1182/blood.2021014497 · Cited by 57
Self-citationFrey, N. V. (2022) · Blood · doi:10.1182/blood.2021014892 · Cited by 57
Cherng, H.-J. J., Sun, R., Sugg, B., Irwin, R., Yang, H., Le, C., Deng, Q., Fayad, L., Fowler, N. H., Parmar, S., et al. (2022) · Blood · doi:10.1182/blood.2022015601 · Cited by 55
Self-citationRoschewski, M. J., Phelan, J. D., & Wilson, W. H. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000450 · Cited by 60
A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity
Gavriilaki, E., Sakellari, I., Gavriilaki, M., & Anagnostopoulos, Α. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113886 · Cited by 58
Lee, J., Sheen, J. H., Lim, O., Lee, Y. J., Ryu, J., Shin, D., Kim, Y. Y., & Kim, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-74772-9 · Cited by 54
Xue, L., Yi, Y., Xu, Q., Wang, L., Yang, X., Zhang, Y., Hua, X., Chai, X., Yang, J., Chen, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00299-6 · Cited by 57
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Fleischmann, M., Schnetzke, U., Hochhaus, A., & Scholl, S. (2021) · Cancers · doi:10.3390/cancers13225722 · Cited by 59
Follicular lymphoma: The long and winding road leading to your cure?
Gordon, M. J., Smith, M. R., & Nastoupil, L. J. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.100992 · Cited by 56
Zurko, J. C., Nizamuddin, I. A., Epperla, N., David, K. A., Cohen, J. B., Moyo, T. K., Ollila, T. A., Hess, B. T., Roy, I., Ferdman, R., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008240 · Cited by 54
Revolutionising health care: Exploring the latest advances in medical sciences
Mahara, G., Tian, C., Xu, X., & Wang, W. (2023) · Journal of Global Health · doi:10.7189/jogh.13.03042 · Cited by 65
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy
Ventin, M., Cattaneo, G., Maggs, L., Arya, S., Wang, X., & Ferrone, C. R. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4504 · Cited by 64
Cardiovascular Considerations During Cancer Therapy
Leong, D. P., Waliany, S., Abdel-Qadir, H. M., Atkins, K. M., Neilan, T. G., Lang, N. N., Liu, J. E., Blaes, A. H., Mian, H. S., Moore, H., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.06.005 · Cited by 63
Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 65
“19 This has not been observed in adults with non-Hodgkin's lymphoma treated with the same product, 260 but it is unclear if this is related to the patient population or underlying disease.”
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
Lu, Y., & Fu, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02334-6 · Cited by 58
CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
Hopfinger, G., Jaeger, U., & Worel, N. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000185 · Cited by 56
Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia
Zhang, H., Gan, W., Hao, W., Wang, P., Li, Z.-Y., & Chang, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00685 · Cited by 54
Abramson, H. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155192 · Cited by 54
Laude, M., Lebras, L. L., Sesques, P., Ghesquières, H., Favre, S., Bouabdallah, K. K., Croizier, C., Guièze, R., Rochelle, L. D. L., Gyan, E., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26068 · Cited by 54
Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinicPreprint
Bewersdorf, J. P., & Abdel-Wahab, O. I. (2022) · Genes & Development · doi:10.1101/gad.349368.122 · Cited by 53
Rejeski, K., Kunz, W. G., Rudelius, M., Bücklein, V., Blumenberg, V., Schmidt, C., Karschnia, P., Schöberl, F., Dimitriadis, K., von Baumgarten, L., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-020-05755-4 · Cited by 53
Optimization of CAR-T Cell-Based Therapies Using Small-Molecule-Based Safety Switches
Zheng, Y., Nandakumar, K. S., & Cheng, K. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02054 · Cited by 55
Shouse, G., Kaempf, A. J., Gordon, M. J., Artz, A. S., Yashar, D., Sigmund, A. M., Smilnak, G., Bair, S. M., Mian, A., Fitzgerald, L. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009309 · Cited by 53
Self-citationHan, M. W., Jeong, S. Y., Suh, C. H., Park, H., Guenette, J. P., Huang, R. Y., Kim, K. W., & Yoon, D. H. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1392831 · Cited by 57
“Other abnormalities, including leptomeningeal enhancement and multifocal microhemorrhage, have also been reported (5).”
BackgroundHashmi, H., Bachmeier, C. A., Chávez, J. C., Song, J., Hussaini, M., Krivenko, G. S., Nishihori, T., Kotani, H., Davila, M. L., Locke, F. L., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16155 · Cited by 53
Dreger, P., Fenske, T. S., Montoto, S., Pasquini, M. C., Sureda, A. M., & Hamadani, M. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.12.771 · Cited by 53
Safety of CAR T-cell therapy in kidney transplant recipients
Mamlouk, O., Nair, R. K., Iyer, S. P., Edwards, A. R., Neelapu, S. S., Steiner, R. E., Adkins, S., Hawkins, M., Saini, N. Y., Devashish, K., et al. (2020) · Blood · doi:10.1182/blood.2020008759 · Cited by 53
Figura, N. B., Robinson, T. J., Sim, A. J., Wang, X., Cao, B., Chávez, J. C., Shah, B. D., Khimani, F., Lazaryan, A., Davila, M. L., et al. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.06.038 · Cited by 53
CAR T cell therapy in B-cell acute lymphoblastic leukaemia: Insights from mathematical models
León‐Triana, O., Sabir, S., Calvo, G. F., Belmonte-Beitia, J., Chulián, S., Martínez-Rubio, Á., Rosa, M., Pérez‐Martínez, A., Ramírez, M. R., & Pérez‐García, V. M. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105570 · Cited by 51
Liu, X., Zhang, Y., Li, K., Liu, Y., Xu, J., Ma, J., An, L., Wang, H., & Chu, X. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101085 · Cited by 52
Toxicities following CAR-T therapy for hematological malignancies
Hernani, R., Benzaquen, A. O., & Solano, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102479 · Cited by 55
Cardiovascular toxicity of immune therapies for cancer
Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 61
Targeting cytokine networks in neuroinflammatory diseases
Becher, B., Derfuss, T. J., & Liblau, R. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01026-y · Cited by 56
“One study indicated that tocilizumab treatment does not have an impact on ICANs or might increase the risk 192 whereas other studies did not see this effect 188,193 .”
Torphy, R. J., Schulick, R. D., & Zhu, Y. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23179 · Cited by 54
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope
Hernández-López, A., Téllez‐González, M. A., Mondragón‐Terán, P., & Meneses‐Acosta, A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.720692 · Cited by 52
George, P., Dasyam, N., Giunti, G., Mester, B., Bauer, E., Andrews, B., Perera, T., Ostapowicz, T., Frampton, C. M., Li, P., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034629 · Cited by 51
Ogasawara, K., Dodds, M., Mack, T. R., Lymp, J. F., Dell’Aringa, J., & Smith, J. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01039-5 · Cited by 51
Hadidi, S. A., Schinke, C., Thanendrarajan, S., Zangari, M., & van Rhee, F. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.8161 · Cited by 51
CAR T‐cell therapy in large B cell lymphoma
Boardman, A. P., & Salles, G. (2023) · Hematological Oncology · doi:10.1002/hon.3153 · Cited by 53
Self-citationSidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Khouri, J., Dima, D., Atrash, S., Voorhees, P. M., Simmons, G. L., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283940 · Cited by 54
Self-citationGagelmann, N., Bishop, M. R., Ayuk, F. A., Bethge, W. A., Glaß, B., Sureda, A. M., Pasquini, M. C., & Kröger, N. M. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.01.074 · Cited by 51
Self-citationCD5 deletion enhances the antitumor activity of adoptive T cell therapies
Patel, R. P., Ghilardi, G., Zhang, Y., Chiang, Y., Xie, W., Guruprasad, P., Kim, K. H., Chun, I., Angelos, M. G., Pajarillo, R., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adn6509 · Cited by 55
Self-citationOutcome correlates of approved CD19-targeted CAR T cells for large B cell lymphoma
Bock, T., Colonne, C. K., Fiorenza, S., & Turtle, C. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-00992-5 · Cited by 53
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis
Hou, K., Yu, Z., Jia, Y., Fang, H., Shao, S., Huang, L., & Feng, Y. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103010 · Cited by 52
Yang, M., Wang, L., Ni, M., Neuber, B., Wang, S., Gong, W., Sauer, T., Sellner, L., Schubert, M., Hückelhoven‐Krauss, A., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.608167 · Cited by 52
Garcia-recio, M., Wudhikarn, K., Pennisi, M., Alonso-Trillo, R., Flynn, J., Shouval, R., Afuye, A., Silverberg, M. L., Batlevi, C., Dahi, P., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.10.022 · Cited by 46
Vector engineering, strategies and targets in cancer gene therapy
Singh, V., Khan, N., & Jayandharan, G. R. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00331-7 · Cited by 55
Steiner, R. E., Banchs, J. A., Koutroumpakis, E., Becnel, M., Gutiérrez, C., Strati, P., Pinnix, C. C., Feng, L., Rondón, G., Claussen, C. M., et al. (2021) · Haematologica · doi:10.3324/haematol.2021.280009 · Cited by 51
Self-citationEmerging therapies in mantle cell lymphoma
Hanel, W. G., & Epperla, N. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00914-1 · Cited by 50
CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
Li, T., Zhao, L., Zhang, Y., Xiao, Y., Wang, D., Huang, L., Ma, L., Chen, L., Liu, S., Long, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01306 · Cited by 50
Noh, K.-E., Lee, J., Choi, S.-Y., Jung, N.-C., Nam, J.-H., Oh, J.-S., Song, J. Y., Seo, H. G., Wang, Y., Lee, H. S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168706 · Cited by 52
Voorhees, T. J., Zhao, B., Oldan, J. D., Hucks, G., Khandani, A. H., Dittus, C. E., Smith, J. K., Morrison, J. K., Cheng, C. J. A., Ivanova, A., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005385 · Cited by 50
Borogovac, A., Keruakous, A. R., Bycko, M., Chakrabarty, J. H., Ibrahimi, S., Khawandanah, M. O., Selby, G. B., Yuen, C. H.-L., Schmidt, S. A., Autry, M. T., et al. (2022) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01664-z · Cited by 50
CAR-T-Derived Extracellular Vesicles: A Promising Development of CAR-T Anti-Tumor Therapy
Pagotto, S., Simeone, P., Brocco, D., Catitti, G., Bellis, D. D., Vespa, S., Pietro, N. D., Marinelli, L., Stefano, A. D., Veschi, S., et al. (2023) · Cancers · doi:10.3390/cancers15041052 · Cited by 53
Recognizing, defining, and managing CAR-T hematologic toxicities
Rejeski, K., Subklewe, M. S., & Locke, F. L. (2023) · Hematology · doi:10.1182/hematology.2023000472 · Cited by 52
Bajwa, A., Zhao, Q., Geer, M. J., Lin, C., Westholder, J. S., Maakaron, J. E., Ghosh, M., Frame, D. G., Galal, A., Tossey, J., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013688 · Cited by 50
“1,4 Although these treatments have demonstrated ef fi cacy in the management of CRS and ICANS, there remains a subset of patients who experience toxicities refractory to fi rst-line treatments.”
Locke, F. L., Go, W. Y., & Neelapu, S. S. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3869 · Cited by 51
Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Alhabbab, R. Y. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00312 · Cited by 51
Bechman, N., & Maher, J. F. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1857361 · Cited by 51
Maillet, D., Belin, C., Moroni, C., Cuzzubbo, S., Ursu, R., Sirven-Villaros, L., Blasi, R. D., Thiéblemont, C., & Carpentier, A. F. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab077 · Cited by 51
Meir, J., Abid, M. A., & Abid, M. B. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.09.016 · Cited by 51
Investigational drugs for the treatment of diffuse large B-cell lymphoma
Patriarca, A., & Gaïdano, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1855140 · Cited by 48
Meng, J., Wu, X., Sun, Z., Xun, R., Liu, M., Hu, R., & Huang, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.698607 · Cited by 48
Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways
Ellebrecht, C. T., Maseda, D., & Payne, A. S. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.04.040 · Cited by 50
Feeder Cells at the Interface of Natural Killer Cell Activation, Expansion and Gene Editing
Gurney, M., Kundu, S., Pandey, S., & O'Dwyer, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802906 · Cited by 42
Hoogland, A. I., Barata, A., Logue, J., Kommalapati, A., Hyland, K. A., Nelson, A. M., Eisel, S. L., Small, B. J., James, B. W., Christy, S. M., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.023 · Cited by 51
Tomar, S., Zhang, J., Khanal, M., Hong, J., Venugopalan, A. K., Jiang, Q., Sengupta, M., Miettinen, M., Li, N., Pastan, I. H., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0073 · Cited by 50
Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
Rentsch, V., Seipel, K., Banz, Y., Wiedemann, G., Porret, N. A., Bacher, U., & Pabst, T. (2022) · Cancers · doi:10.3390/cancers14102516 · Cited by 49
Alkhateeb, H. B., Mohty, R., Greipp, P. T., Bansal, R., Hathcock, M. A., Rosenthal, A. C., Murthy, H. S., Kharfan‐Dabaja, M. A., Villasboas, J. C., Bennani, N. N., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00707-4 · Cited by 49
Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL
Zhang, J., Gu, Y., & Chen, B. (2023) · Cancer Management and Research · doi:10.2147/cmar.s400013 · Cited by 56
García-Calderón, C. B., Sierro-Martínez, B., García‐Guerrero, E., Sanoja-Flores, L., Muñoz-García, R., Ruiz-Maldonado, V., Jiménez‐León, M. R., Delgado‐Serrano, J., Molinos-Quintana, Á., Guijarro-Albaladejo, B., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1152498 · Cited by 51
Cichocki, F. M., Zhang, B., Wu, C.-Y., Chiu, E., Day, A., O’Connor, R. S., Yackoubov, D., Simantov, R., McKenna, D. H., Cao, Q., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3341 · Cited by 49
Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer
Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 49
Kittai, A. S., Bond, D. A., Huang, Y., Bhat, S. A., Blyth, E., Byrd, J. C., Chávez, J. C., Davids, M. S., Cruz, J. P. D., Dowling, M. R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00033 · Cited by 49
Self-citationDerigs, P., Schubert, M., Dreger, P., Schmitt, A., Yousefian, S., Haas, S. F., Röthemeier, C., Neuber, B., Hückelhoven‐Krauss, A., Brüggemann, M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02392-7 · Cited by 48
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma
Bartlett, N. L., Hahn, U., Kim, W. S., Fleury, I., Laribi, K., Bergua, J., Bouabdallah, K. K., Forward, N. A., Bijou, F. D., Macdonald, D. A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-02242 · Cited by 49
Self-citationLocke, F. L., Munoz, J. L., Tees, M. T., Lekakis, L. J., de Vos, S., Nath, R., Stevens, D. A., Malik, S. A., Shouse, G., Hamadani, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01933 · Cited by 52
Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
Itzhaki, O., Jacoby, E., Nissani, A., Levi, M., Nagler, A., Kubi, A., Brezinger, K., Brayer, H., Zeltzer, L., Rozenbaum, M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000148 · Cited by 54
Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy
Cao, W., Wei, J., Wang, N., Xu, H., Xiao, M., Huang, L., Cao, Y., Li, C., Xiao, Y., Gu, C., et al. (2020) · Blood · doi:10.1182/blood.2020004907 · Cited by 48
Liao, Q., He, H., Mao, Y., Ding, X., Zhang, X., & Xu, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00238-9 · Cited by 48
Adoptive T cell therapy: Boosting the immune system to fight cancer
León, E. C., Ranganathan, R., & Savoldo, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101437 · Cited by 48
Heß, G., Dreyling, M. H., Obéric, L., Giné, E., Zinzani, P. L., Linton, K., Vilmar, A. C., Jerkeman, M., Chen, J. M. H., Ohler, A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18519 · Cited by 48
Self-citationWang, Z., Wang, J., Lan, T., Zhang, L., Yan, Z., Zhang, N., Xu, Y., & Tao, Q. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1135384 · Cited by 53
Metadata
- Authors
- Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., Awasthi, R., Chu, J., Anak, Ö., Salles, G., & Maziarz, R. T.
- Affiliations
- The University of Sydney (AU)
- From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago Medicine, Chicago (M.R.B.); Peter MacCallum Cancer Centre, St. Vincent’s Hospital and University of Melbourne, Melbourne, VIC (C.S.T.), and the Royal Prince Alfred Hospital and Department of Medicine, University of Sydney, Sydney (P.J.H.) — both in Australia; Winship Cancer Institute of Emory University, Bone Marrow and Stem Cell...
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 45-56
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2903062212
- Cited by
- 4,112
- References
- 29
- Citations by year
- 2026: 363 · 2025: 507 · 2024: 593 · 2023: 593 · 2022: 693 · 2021: 624 · 2020: 502 · 2019: 218
- FWCI
- 125.46
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- tisagenlecleucel, CAR T-cell therapy, diffuse large B-cell lymphoma, relapsed/refractory lymphoma, CD19, autologous stem cell transplantation, cytokine release syndrome, neurological adverse events, relapse-free survival, complete response, immune checkpoint molecules
- MeSH terms
- Receptors, Chimeric Antigen, Progression-Free Survival, Adult, Aged, Female, Humans, Male, Middle Aged, Receptors, Antigen, T-Cell, Recurrence, Survival Analysis, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Young Adult, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
